CSL Behring is joining the chase for a genetic treatment for hemophilia by acquiring a uniQure gene therapy that’s already in late-stage testing.
King of Prussia, PA-based CSL Behring is paying $450 million up front to acquire the uniQure (NASDAQ: QURE) asset, etranacogene dezaparvovec (“EtranaDez” for short), the companies announced late Wednesday. Netherlands-based uniQure will complete the Phase 3 test of the hemophila B gene therapy and will also be responsible for submitting an application for FDA review, expenses that CSL Behring has agreed to reimburse. If the bleeding disorder therapy reaches the market, the agreement calls for the company… Read more »
UNDERWRITERS AND PARTNERS